Business Development Deal Architecture
  • Search OnBioBD:

  • OnBioBD OldSkool NEWS:

    - OnBioVC 4Q11 Trend Analysis, now available
    - OnBioVC 1Q12 White Paper, now available
    - OnBioVC 1Q12 Trend Analysis, coming soon

  • FDA Registered Contract Manufacturer

Edison Pharmaceuticals (Mountain View, CA), a clinical-stage pharmaceutical company developing small molecules to treat mitochondrial disease, closed a $20M Series F financing. Participants include Mitsui & Co. Global Investment.

AcuFocus (Irvine, CA) a commercial-stage medical device company focused on corneal inlays for near-vision loss, closed a $40M Series F financing. Participants include Medtronic, SV Life Sciences, Versant Ventures, Carlyle Group, Accuitive Medical Ventures and Bausch & Lomb.

Antisense Pharma (Germany) a clinical-stage biopharmaceutical company focused on antisense gene silencing for pancreatic cancer, malignant melanoma and colorectal cancer, closed a $11M Series F financing. Participants include MIG Fonds and Global Asset Fund. Thanx for your patience as we catch-up.

Awarepoint (San Diego, CA) a commercial-stage hospital data analysis and automation software suite focused on real-time patient care progression, closed a $27M Series F financing. Participants include Kleiner Perkins, Top Tier Capital Partners, Cardinal Partners, Venrock and Jafco Ventures. Thanx for your patience as we catch-up.

Entellus Medical (Maple Grove, MN) a commercial-stage medical device company focused on minimally invasive treatments for chronic sinusitis, closed a $35M Series E financing. Participants include Covidien Ventures, SV Life Sciences, Essex Woodlands, Split Rock Partners and Greenspring Associates. Thanx for your patience as we catch-up.

NovaSom (Glen Burnie, MD) a commercial-stage medical device company focused on the diagnosis of obstructive sleep apnea, closed a $35M Series F financing. Participants include Safeguard Scientifics, TPG Biotech and Quaker BioVentures.

Chimerix (Durham, NC) a clinical-stage pharma company developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $45M Series F financing. Participants include Pappas Ventures, Morningside Group, Sanderling Ventures, Canaan Partners, Alta Partners, Asset Management Co., Frazier Healthcare Ventures and New Leaf Venture Partners.

Symphogen (Denmark) a clinical-stage developer of recombinant polyclonal antibodies for the treatment of cancer and infectious and autoimmune diseases, closed a $135.4M Series F financing. Participants include Essex Woodlands Health Ventures, Novo, and Pensionskassernes Administration.

Small Bone Innovations (Morrisville, PA) a commercial-stage a small bone and joint device company focused on arthroplasty, fixation, trauma and biologic solutions, closed a $15M Series F financing. Participants have included 3i Group, NGN Capital, Trevi Health Ventures, Viscogliosi Brothers, Vollin Holdings and The Family Office Co.

EndoGastric Solutions (Redmond, WA) a commercial-stage medical device company focused on endoluminal procedures for the treatment of upper gastrointestinal diseases, including gastroesophageal reflux disease (GERD) and other GI disorders, closed a $30M Series F financing. Participants have included Canaan Partners, Radius Ventures, Advanced Technology Ventures, Chicago Growth Partners, DeNovo Ventures, Foundation Medical Partners, MPM Capitaland […]

Pacific Biosciences (Menlo Park, CA) developer of single molecule real-time nucleic acid and protein sequencing system closed a $50M Series F financing. Participants include Gen-Probe, Monsanto, the Wellcome Trust, Sutter Hill Ventures, Deerfield Management, Intel Capital, Morgan Stanley, Redmile Group, T. Rowe Price, Mohr Davidow Ventures, Kleiner Perkins Caufield and Byers, Alloy Ventures, Maverick Capital, […]

Eucodis Bioscience (Vienna) a commercial-stage company focused on the development, customization, manufacture and marketing of industrial enzymes, closed a $2.7m Series B financing. Participants include Pontis Capital, Wiener Wachstumsfonds and Arax Capital Partners.

BioVex (Woburn, MA) a clinical-stage biologics company focused on metastatic melanoma, head and neck, pancreatic and colo-rectal cancer, closed a $30M Series F bringing the entire round to $70M. Participants have included Morningside Venture, Ventech, MVM Life Science Partners, Sectoral Asset Management, Ysios Capital Partners, Forbion Capital Partners, Credit Agricole Private Equity, Harris & Harris […]

« Previous Entries  Next Page »

to top of page...